Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of IPO & Placements for Aequitas Research. At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%. 
Prior to Aequitas. I was heading Content Strategy for Smartkarma, along with covering IPOs & Placement. In an earlier life I have covered ASEAN property and the banking space in India.

Head of Research, IPOs & Placements

China's Healthcare Reform Consolidates Drug Distribution and Cuts Manufacturer Margins

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

China Biologic Products / Equity Capital Markets

Warburg Pincus plans to raise approximately US$370m though a partial sale of its stake in China Biological Products (CBPO). The deal scores a marginally positive score on our framework, given its splendid track record. We spoke to a medical expert to get their view on the stock as well, and they reaffirmed the positive longer term outlook for the stock.However, the sell down represents 13.2% of the company's outstanding stock. While the indicative discount is only 6-8%. Furthermore, the previous…

Warburg Pincus plans to raise approximately US$370m though a partial sale of its stake in China Biological Products (CBPO). The deal scores a marginally positive score on our framework, given its splendid track record. We spoke to a medical expert to get their view on the stock as well, and they reaffirmed the positive longer term outlook for the stock.However, the sell down represents 13.2% of the company's outstanding stock. While the indicative discount is only 6-8%. Furthermore, the previous…

China Biologic Products - Great Track Record Should Help to Digest the Large Deal